Immuneering (NASDAQ:IMRX) Issues Earnings Results

Immuneering (NASDAQ:IMRX) issued its earnings results on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01), FiscalAI reports. The company had revenue of $0.36 million for the quarter.

Immuneering Stock Up 0.1%

IMRX traded up $0.01 during trading on Thursday, reaching $4.39. 527,768 shares of the company’s stock were exchanged, compared to its average volume of 1,431,351. Immuneering has a fifty-two week low of $2.90 and a fifty-two week high of $10.08. The company has a market capitalization of $284.36 million, a P/E ratio of -3.76 and a beta of 0.43. The business has a 50 day moving average price of $4.60 and a 200 day moving average price of $4.98.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IMRX. Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. UBS Group set a $14.00 price target on Immuneering in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. HC Wainwright began coverage on shares of Immuneering in a research note on Thursday. They issued a “buy” rating and a $14.00 price objective on the stock. Finally, Chardan Capital upgraded shares of Immuneering to a “strong-buy” rating in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.50.

Trending Headlines about Immuneering

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: Analyst sentiment improved. HC Wainwright initiated coverage with a “Buy” rating and a $14 price target, implying substantial upside from recent levels. Chardan Capital also upgraded Immuneering to “Strong Buy.” HC Wainwright starts Immuneering at Buy
• Positive Sentiment: Atebimetinib produced promising early pancreatic cancer data. Immuneering reported a 17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy. The company said 84% of evaluable patients were weight-stable or gained weight after three months, supporting the drug’s potential tolerability and differentiation.
• Positive Sentiment: Development momentum continued. The pivotal Phase 3 MAPKeeper 301 trial is dosing patients and has more than 30 study locations. Immuneering also highlighted peer-reviewed Cancer Research findings showing broad preclinical activity across RAS- and RAF-mutant tumors. Topline Phase 3 data are expected in mid-2028.
• Positive Sentiment: Liquidity remains a key support. The company ended the second quarter with $182.7 million in cash, cash equivalents and marketable securities, and expects its cash runway to extend into 2029 under current plans.
• Neutral Sentiment: The company remains entirely dependent on clinical execution. Immuneering plans additional atebimetinib combination data in late 2026 and a Phase 2 lung cancer trial, but its approach has not yet been validated in a registrational trial.
• Negative Sentiment: Quarterly results were slightly below expectations. Immuneering reported a second-quarter loss of $0.27 per share versus the $0.26 consensus estimate, while revenue was only $0.36 million. The $17.3 million net loss increased from $14.4 million a year earlier, reflecting higher research and development spending.
• Negative Sentiment: Cash declined from year-end. Cash, cash equivalents and marketable securities fell from $217.0 million at December 31, 2025, to $182.7 million at June 30, 2026, highlighting the ongoing financing risk typical of a loss-making biotechnology company.

Hedge Funds Weigh In On Immuneering

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Immuneering in the 1st quarter valued at about $32,000. SummitTX Capital L.P. bought a new position in shares of Immuneering in the fourth quarter worth about $69,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Immuneering in the 3rd quarter valued at about $70,000. Ausdal Financial Partners Inc. bought a new position in shares of Immuneering in the fourth quarter valued at $72,000. Finally, Moors & Cabot Inc. purchased a new stake in shares of Immuneering during the third quarter valued at approximately $77,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.